Maspin subcellular expression in wild-type and mutant TP53 gastric cancers

Table 1 Clinicopathological characteristics of gastric cancer patients

Clinicopathological parameter		Number (n = 266), n (%)
Age (yr)	≤ 60	96 (36.09)
	> 60	170 (63.91)
Gender	Male	175 (65.78)
	Female	91 (34.22)
Localization	Proximal stomach	108 (40.60)
	Middle third	47 (17.67)
	Distal third and antrum	95 (35.71)
	Diffuse localization	16 (6.02)
Macroscopic aspect (Bormann’s type)	Polypoid	21 (7.89)
	Ulcerated	62 (23.31)
	Ulcero-infiltrative	151 (56.77)
	Diffusely infiltrative	32 (12.03)
Microscopic aspect	Adenocarcinoma G1+2	75 (28.20)
	Adenocarcinoma G3	76 (28.57)
	Papillary carcinoma	10 (3.76)
	Non-mucinous poorly cohesive	53 (19.92)
	Signet ring cell carcinoma	25 (9.40)
	Diffuse micro-glandular	27 (10.15)
Budding degree (Dyscohesivity rate)	Nodular growth	34 (12.78)
	1-4 buds/HPF	17 (6.39)
	5-9 buds/HPF	50 (18.80)
	≥ 10 buds/HPF	60 (22.56)
	Diffuse growth	105 (39.47)
Associated intestinal metaplasia	Yes	87 (32.71)
	No	179 (67.29)
pT stage	pT1	22 (8.27)
	pT2	15 (5.64)
	pT3	66 (24.81)
	pT4	163 (61.28)
pN stage	pN0	53 (19.92)
	pN1	45 (16.92)
	pN2	51 (19.17)
	pN3	117 (43.99)
Dukes-MAC-like stage	T1N0	10 (3.76)
	T1N1-3	12 (4.51)
	T2N0	7 (2.63)
	T2N1-3	8 (3)
	T3N0	13 (4.89)
	T3N1-3	53 (19.93)
	T4N0	23 (8.65)
	T4N1-3	140 (52.63)

G1: Well differentiated, G2: Moderately differentiated, G3: Poorly differentiated; pT: Depth of tumor infiltration; pN: Lymph node status.